Swiss National Bank Purchases 2,700 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Swiss National Bank raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 59,000 shares of the company’s stock after acquiring an additional 2,700 shares during the period. Swiss National Bank’s holdings in Keros Therapeutics were worth $934,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of KROS. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Keros Therapeutics in the 4th quarter worth approximately $461,000. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Keros Therapeutics by 7.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company’s stock worth $4,427,000 after purchasing an additional 19,562 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Keros Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company’s stock worth $1,549,000 after buying an additional 2,462 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in Keros Therapeutics by 1,910.2% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 74,255 shares of the company’s stock worth $1,175,000 after acquiring an additional 70,561 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on KROS. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Truist Financial lowered their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Finally, Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Performance

KROS stock opened at $10.79 on Friday. The firm has a 50 day moving average price of $11.15 and a 200-day moving average price of $34.44. Keros Therapeutics, Inc. has a 52-week low of $9.78 and a 52-week high of $72.37. The firm has a market capitalization of $437.66 million, a price-to-earnings ratio of -2.07 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.